IDEAS home Printed from
   My bibliography  Save this article

Formulation of a Success Model in Pharmaceutical R&D


  • Hyunju Rachel Kim


Recently, pharmaceutical R&D has been demanded to increase productivity in terms of time efficiency and innovation as well. There have been discontinuous challenges coming up in this industry, such as globalized R&D competition, stricter regulation, lengthy process of clinical trials, and so on. Considering external changes, high competition, and discontinuities in the industry, it is a good time to redefine the concept of success in pharmaceutical R&D. Thus, this article attempts to formulate a new success model in pharmaceutical R&D, through contextualizing the industry’s success factors.

Suggested Citation

  • Hyunju Rachel Kim, 2014. "Formulation of a Success Model in Pharmaceutical R&D," SAGE Open, , vol. 4(1), pages 21582440145, March.
  • Handle: RePEc:sae:sagope:v:4:y:2014:i:1:p:2158244014527986
    DOI: 10.1177/2158244014527986

    Download full text from publisher

    File URL:
    Download Restriction: no

    References listed on IDEAS

    1. Weijan Shan & Gordon Walker & Bruce Kogut, 1994. "Interfirm cooperation and startup innovation in the biotechnology industry," Strategic Management Journal, Wiley Blackwell, vol. 15(5), pages 387-394, June.
    2. H. Igor Ansoff, 1987. "The emerging paradigm of strategic behavior," Strategic Management Journal, Wiley Blackwell, vol. 8(6), pages 501-515, November.
    3. Zucker, Lynne G. & Darby, Michael R., 1997. "Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm," Research Policy, Elsevier, vol. 26(4-5), pages 429-446, December.
    4. Orsenigo, L. & Pammolli, F. & Riccaboni, Massimo, 2001. "Technological change and network dynamics: Lessons from the pharmaceutical industry," Research Policy, Elsevier, vol. 30(3), pages 485-508, March.
    5. Chan, Su Han & Martin, John D. & Kensinger, John W., 1990. "Corporate research and development expenditures and share value," Journal of Financial Economics, Elsevier, vol. 26(2), pages 255-276, August.
    6. Light, Donald W. & Warburton, Rebecca N., 2005. "Setting the record straight in the reply by DiMasi, Hansen and Grabowski," Journal of Health Economics, Elsevier, vol. 24(5), pages 1045-1048, September.
    7. Yu-Ting Cheng & Andrew H. Van de Ven, 1996. "Learning the Innovation Journey: Order out of Chaos?," Organization Science, INFORMS, vol. 7(6), pages 593-614, December.
    8. James P. Walsh, 1995. "Managerial and Organizational Cognition: Notes from a Trip Down Memory Lane," Organization Science, INFORMS, vol. 6(3), pages 280-321, June.
    9. Thomas A. Abbott & John A. Vernon, 2007. "The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 293-306.
    10. C. K. Prahalad & Richard A. Bettis, 1986. "The dominant logic: A new linkage between diversity and performance," Strategic Management Journal, Wiley Blackwell, vol. 7(6), pages 485-501, November.
    11. Gary P. Pisano, 1994. "Knowledge, Integration, and the Locus of Learning: An Empirical Analysis of Process Development," Strategic Management Journal, Wiley Blackwell, vol. 15(S1), pages 85-100, December.
    12. David J. Teece & Gary Pisano & Amy Shuen, 1997. "Dynamic capabilities and strategic management," Strategic Management Journal, Wiley Blackwell, vol. 18(7), pages 509-533, August.
    13. Trochim, W.M. & Cabrera, D.A. & Milstein, B. & Gallagher, R.S. & Leischow, S.J., 2006. "Practical challenges of systems thinking and modeling in public health," American Journal of Public Health, American Public Health Association, vol. 96(3), pages 538-546.
    14. Luigi Orsenigo & Fabio Pammolli & Massimo Riccaboni & Andrea Bonaccorsi & Giuseppe Turchetti, 1997. "The Evolution of Knowledge and the Dynamics of an Industry Network," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 1(2), pages 147-175, June.
    15. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    Full references (including those not matched with items on IDEAS)


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:sagope:v:4:y:2014:i:1:p:2158244014527986. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (SAGE Publications). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.